Wetirin 0.2 mg tablets

Patient Information Leaflet

Introduction

Patient Information Leaflet

Wetirin 0.2 mg tablets

Desmopressin

Read the entire leaflet carefully before you start taking this medicine, because it contains important information for you.

• Keep this leaflet, as you may need to read it again.

• If you have any questions, consult your doctor or pharmacist.

• This medicine has been prescribed for you only and must not be given to other people, even if they have the same symptoms as you, because it could harm them.

• If you experience any adverse effects, consult your doctor or pharmacist, even if they are adverse effects not listed in this leaflet. See section 4.

Leaflet contents:

1. What Wetirin is and what it is used for
2. What you need to know before taking Wetirin
3. How to take Wetirin
4. Possible side effects
5. How to store Wetirin

6. Contents of the pack and other information

1. What Wetirin is and what it is used for

Wetirin contains desmopressin, a structural analogue of the natural pituitary hormone arginine vasopressin. Desmopressin belongs to the group of antidiuretic hormone (vasopressin) analogues, which temporarily reduce the amount of urine produced by the body.

Wetirin is used to treat central diabetes insipidus (continuous thirst and continuous excretion of very dilute urine) and primary nocturnal enuresis (nighttime urinary incontinence) in patients over 5 years of age who have normal urine-concentrating ability.

2. What you need to know before starting to take Wetirin

Do not take Wetirin

• if you are allergic to the active substance or to any of the other components of this medicine (listed in section 6),

• if you have habitual polydipsia (prolonged excessive thirst) or psychogenic polydipsia (emotional or psychological origin),

• if you suffer from heart failure or other conditions requiring treatment with diuretics (medications that increase urine secretion),

• if you have moderate or severe renal insufficiency,

• if you have known hyponatremia (low sodium levels in the blood),

• if you have syndrome of inappropriate ADH secretion (antidiuretic hormone).

Warnings and precautions

Consult your doctor or pharmacist before starting to take this medication.

If you have primary nocturnal enuresis, take special care to restrict fluid intake, avoiding drinking from 1 hour before administration until 8 hours after.

Treatment without simultaneous reduction of water intake may cause water retention and/or decreased sodium levels in the blood, with or without symptoms and warning signs (headache, nausea/vomiting, weight gain, and in severe cases, seizures). See section 4.

Special care must be taken to avoid decreased sodium levels in the blood in the following cases:

• Systemic infections, fever, and gastroenteritis (syndrome of inappropriate antidiuretic hormone secretion).

• Risk of increased intracranial pressure.

• Imbalance in body water and electrolyte content.

• Concomitant treatment with medications that may induce nephrogenic diabetes insipidus themselves, such as: antidepressants like tricyclic antidepressants (e.g., amitriptyline), selective serotonin reuptake inhibitors (e.g., fluoxetine), chlorpromazine, and carbamazepine.

• Concomitant treatment with NSAIDs (non-steroidal anti-inflammatory drugs) such as acetylsalicylic acid.

Use of other medicines and Wetirin

Inform your doctor or pharmacist if you are taking, have recently taken, or might need to take any other medicines.

Wetirin may interact with drugs that can themselves cause diabetes insipidus, such as: antidepressant medications of the tricyclic type, for example amitriptyline, selective serotonin reuptake inhibitors, for example fluoxetine, chlorpromazine, and carbamazepine, as well as certain antidiabetic agents of the sulfonylurea group, especially chlorpropamide.

Non-steroidal anti-inflammatory drugs (NSAIDs) may induce water retention/decreased blood sodium levels.

Caution is advised if you are being treated with loperamide (a medicine used to treat diarrhea), as it may increase the risk of water retention and decreased blood sodium levels.

Use of Wetirin with food and drinks

It is recommended to take Wetirin with food (not high in fat).

It is recommended not to drink fluids with Wetirin.

Pregnancy, lactation and fertility

If you are pregnant or breastfeeding, think you may be pregnant, or are planning to become pregnant, consult your doctor or pharmacist before using this medicine.

There are insufficient clinical data to support its use during pregnancy. Animal studies have not shown fetal risk potential with desmopressin administration.

Desmopressin passes into breast milk, although in small amounts; therefore, if this medicine needs to be administered to a woman who is breastfeeding, replacement of breastfeeding is recommended.

Driving and use of machines

Wetirin does not affect the ability to drive or operate machinery.

Important information about excipients:

This medicine contains lactose. If your doctor has informed you of an intolerance to certain sugars, consult with him before taking this medicine.

3. How to take Wetirin

Follow exactly the instructions for use provided by your doctor. If in doubt, consult your doctor or pharmacist again.

Recommended dose

Central diabetes insipidus: The doctor will adjust the dose individually.

The recommended initial dose is 0.1 mg (one tablet of Wetirin 0.1 mg) taken three times a day. Subsequently, the doctor will adjust the dose according to each patient's response.

The maintenance dose usually ranges between 0.1 mg and 0.2 mg of wetirin (one or two tablets of Wetirin 0.1 mg) three times a day.

The usual total daily dose ranges from 0.2 mg to 1.2 mg of desmopressin.

Primary nocturnal enuresis:

The recommended initial dose is 0.2 mg of wetirin at bedtime. If this dose is not sufficiently effective, it may be increased up to 0.4 mg of wetirin.

It is important to control fluid intake.

If symptoms or signs of water retention and/or decreased blood sodium (headache, nausea and vomiting, weight gain, and in severe cases, seizures) occur, treatment must be discontinued until the patient has recovered. Once treatment is resumed, fluid intake must be strictly controlled.

Swallow the tablet with a glass of water. It is preferable to take it with some food. The tablet should be taken three times a day, preferably with meals in the case of diabetes insipidus. If you are being treated for nocturnal enuresis, it is recommended to take the tablet at bedtime with dinner, once daily.

If you feel that the effect of Wetirin is too strong or too weak, inform your doctor or pharmacist.

Duration of treatment

Your doctor will determine how long your treatment with Wetirin should last. Do not stop the treatment prematurely, as it may not achieve the intended effect.

Treatment for nocturnal enuresis will last for 3 months. After this period, your doctor will assess whether continued treatment is necessary. If so, treatment will be resumed, maintaining at least a one-week break.

If you take more Wetirin than you should

In case of overdose or accidental ingestion, contact the Toxicology Information Service at telephone number (91) 562 04 20, indicating the medication and the amount ingested. It is recommended to bring the packaging and the leaflet to the healthcare professional.

If an overdose occurs, the action of desmopressin will be prolonged, and some symptoms may include water retention and/or decreased blood sodium, leading to headache, nausea and vomiting, weight gain, and in severe cases, seizures. It is recommended to discontinue treatment, restrict fluid intake, and provide symptomatic treatment if necessary.

If you forget to take Wetirin

Do not take a double dose to make up for missed doses.

If you stop taking Wetirin

Do not discontinue treatment with this medicine before completing it, as it may not have the intended effect. Only change or discontinue treatment if specifically instructed by your doctor.

If you have any further questions about the use of this medicine, ask your doctor or pharmacist.

If you have any further questions about the use of this product, ask your doctor or pharmacist.

4. Possible adverse effects

Like all medicines, this medicine may cause adverse effects, although not everyone experiences them.

Common (may affect up to 1 in 10 people): Headache.

Uncommon (may affect up to 1 in 100 people): Mood changes, aggression, abdominal pain, nausea, vomiting, diarrhea, bladder and urethral symptoms, peripheral edema, fatigue.

Rare (may affect up to 1 in 1,000 people): Anxiety symptoms, nightmares, mood changes, somnolence, hypertension, irritability.

Frequency not known: Anaphylactic reaction, hyponatremia, dehydration, hypernatremia, abnormal behavior, emotional disorder, depression, hallucinations, insomnia, attention disturbance, psychomotor hyperactivity, seizures, epistaxis, allergic dermatitis, exanthema, sweating, urticaria.

Due to decreased sodium in the blood caused by water retention as a result of treatment, together with reduced fluid intake, headache, nausea, vomiting, low sodium levels, weight gain, and in severe cases, seizures may occur.

Reporting of adverse effects:

If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect not listed in this leaflet. You may also report them directly via the Spanish Pharmacovigilance System for Human Medicinal Products: http;//www.notificaram.es. By reporting adverse effects, you can help provide more information on the safety of this medicine.

5. Storage of Wetirin

Keep this medicine out of the sight and reach of children.

Store in the original container, below 25°C and in a dry place. Do not remove the desiccant from the cap.

Do not use this medicine after the expiry date stated on the packaging, following “EXP”. The expiry date is the last day of the month indicated.

Medicines should not be disposed of via wastewater or household waste. Dispose of unused medicines and their containers at the SIGRE Point at your pharmacy. If you are unsure, ask your pharmacist how to dispose of medicines and containers you no longer need. This will help protect the environment.

6.

Composition of Wetirin 0.2 mg tablets:

• The active substance is desmopressin acetate. Each tablet contains 0.2 mg of desmopressin acetate, equivalent to 0.178 mg of desmopressin base.

• The other components are: monohydrate lactose, potato starch, povidone, and magnesium stearate.

Appearance of the product and contents of the container

The tablets are white, round, and convex, with a unique marking on one side stating "0.2 milligrams".

They are supplied in 30 ml high-density polyethylene bottles with a polypropylene cap and child-resistant closure. A silica gel capsule is included in the cap acting as a desiccant.

The bottle contains 30 tablets.

Marketing Authorization Holder

FERRING, S.A.U

C/ del Arquitecto Sánchez Arcas nº3, 1º

28040 Madrid

Spain

Manufacturer responsible

FERRING GmbH

Wittland 11,

D-24109 Kiel

GERMANY

Date of the most recent review of the package leaflet: November 2020

Detailed and up-to-date information on this medicinal product is available on the website of the Spanish Agency of Medicines and Health Products (AEMPS) http://www.aemps.gob.es/